Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years
12:17pm, Wednesday, 04'th Mar 2026
Iovance Biotherapeutics (IOVA) remains a high-risk, high-reward play, with lifileucel (Amtagvi) now approved for advanced melanoma and 2025 company revenues of $264m. IOVA faces persistent losses, a p
Iovance Biotherapeutics to Present at Upcoming Conferences
08:00am, Thursday, 26'th Feb 2026
SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf
Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why
01:33pm, Wednesday, 25'th Feb 2026
A relative unknown, if you don't watch the biotherapeutics industry, Iovance Biotherapeutics ( NASDAQ:IOVA ) surged 43% in the past week after reporting Q4 2025 earnings on February 24, pushing Reddit
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress
12:06pm, Wednesday, 25'th Feb 2026
Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.
Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)
03:43pm, Tuesday, 24'th Feb 2026
Iovance Biotherapeutics demonstrates improved Q4 results, with $87M revenue and a 50% gross margin (ex-D&A), but remains high-risk/high-reward. AMTAGVI drives IOVA's prospects, with a modeled $1.6B pe
Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy
02:14pm, Tuesday, 24'th Feb 2026
Iovance Biotherapeutics (NASDAQ: IOVA) shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarc
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript
12:57pm, Tuesday, 24'th Feb 2026
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
10:40am, Tuesday, 24'th Feb 2026
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago.
IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?
10:05am, Tuesday, 24'th Feb 2026
Both Iovance Biotherapeutics IOVA and Rigel Pharmaceuticals RIGL are small-cap companies focused on the successful commercialization of their marketed products.
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
07:00am, Tuesday, 24'th Feb 2026
SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
07:00am, Tuesday, 24'th Feb 2026
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE N
1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits
03:15am, Monday, 23'rd Feb 2026
This biotech stock won approval for a cancer treatment a couple of years ago. That treatment is starting to generate revenue growth.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 20'th Feb 2026
SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deli
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
04:05pm, Wednesday, 11'th Feb 2026
SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Rating of “Hold” from Brokerages
01:44am, Friday, 06'th Feb 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA - Get Free Report) has received an average rating of "Hold" from the fourteen research firms that are currently covering the firm, MarketBeat.com reports. T
